Akums Drugs & Pharmaceuticals Ltd (AKUMS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039335,
    "name": "Akums Drugs",
    "stock_name": "Akums Drugs",
    "full_name": "Akums Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/akums-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "447.30",
    "chg": 9.8,
    "chgp": "2.24%",
    "dir": 1,
    "prev_price": "437.50",
    "mcapval": "6,976.00 Cr",
    "mcap": "Small Cap",
    "scripcode": "544222",
    "symbol": "AKUMS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE09XN01023",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.36 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/akums-drugs-10039335-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/akums-drugs-downgraded-to-strong-sell-amid-weak-fundamentals-and-negative-financial-trends-3735195",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugs_mojoScore_3735195.png",
        "date": "2025-11-28 10:05:12",
        "description": "Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Why is Akums Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-akums-drugs-fallingrising-3727211",
        "imagepath": "",
        "date": "2025-11-25 01:51:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>Akums Drugs has been on a losing streak, with the stock falling for five consecutive days and registering a weekly decline of 5.91%, significantly underperforming the Sensex, which remained almost flat with a marginal 0.06% gain over the same period. The stock is trading perilously close to its 52-week low, just 1.67% above the ₹407.4 mark, underscoring the persistent bearish sentiment among investors. Intraday activity further highlighted weakness, with the share price touching a low of ₹411.1, down 2.5% during the session, and a weighted average price indicating that most volume was transacted near these lower levels.</p>\n<p>Technically, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-..."
      },
      {
        "title": "How has been the historical performance of Akums Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-akums-drugs-3709302",
        "imagepath": "",
        "date": "2025-11-17 23:27:20",
        "description": "Answer:\nThe historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected t..."
      },
      {
        "title": "Akums Drugs Faces Financial Challenges Amid Declining Performance Metrics and Rising Costs",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/akums-drugs-pharmaceuticals-financial-trend-declines-from-flat-to-negative-amid-rising-costs-3701333",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugsPharm_fintrenddot_3701333.png",
        "date": "2025-11-14 11:03:32",
        "description": "Akums Drugs & Pharmaceuticals has faced a decline in financial performance for the quarter ending September 2025, despite reporting a higher profit after tax for the nine-month period. Key indicators show rising interest expenses and a significant drop in quarterly PAT, raising concerns about operational efficiency and financial sustainability."
      },
      {
        "title": "Akums Drugs Q2 FY26: Profit Plunges 37% as Margins Compress Under Rising Costs",
        "link": "https://www.marketsmojo.com/news/result-analysis/akums-drugs-q2-fy26-profit-plunges-37-as-margins-compress-under-rising-costs-3715583",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AkumsDrugsPharm_quaterlyResult_3715583.png",
        "date": "2025-11-14 09:46:28",
        "description": "Akums Drugs & Pharmaceuticals Ltd., one of India's leading pharmaceutical contract development and manufacturing organisations, reported a disappointing second quarter for FY2026, with consolidated net profit declining 37.46% year-on-year to ₹40.78 crores from ₹65.21 crores in Q2 FY25. The quarter-on-quarter performance was equally concerning, with profits falling 35.76% from ₹63.48 crores in Q1 FY26. The sharp contraction in profitability comes despite relatively stable revenue, raising questions about operational efficiency and cost management at the ₹6,635 crore market capitalisation company."
      },
      {
        "title": "How has been the historical performance of Akums Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-akums-drugs-3699859",
        "imagepath": "",
        "date": "2025-11-13 23:53:16",
        "description": "Answer:\nThe historical performance of Akums Drugs shows significant fluctuations in key financial metrics over the past three years, culminating in a notable recovery in the fiscal year ending March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, a slight decrease from 4,178.18 crore in March 2024, but an increase from 3,654.82 crore in March 2023. The total operating income mirrored this trend, remaining stable at 4,118.16 crore in March 2025. The total expenditure, excluding depreciation, decreased to 3,653.67 crore from 4,055.20 crore in the previous year, contributing to a significant rise in operating profit (PBDIT) to 516.61 crore, compared to 157.01 crore in March 2024 and 384.06 crore in March 2023. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surg..."
      },
      {
        "title": "Why is Akums Drugs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-akums-drugs-fallingrising-3687448",
        "imagepath": "",
        "date": "2025-11-11 00:27:55",
        "description": "As of 10-Nov, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 439.70, reflecting a decrease of Rs 14.75 or 3.25%. The stock has underperformed its sector by 4.3% today and has been on a consecutive downward trend for the last three days, with a total decline of 6.63% during this period. The stock has also touched an intraday low of Rs 436, indicating significant selling pressure. Over the past year, the stock has generated a return of -44.83%, which is considerably worse than the benchmark Sensex, which has gained 5.09%. Despite a low debt-to-equity ratio and an attractive valuation indicated by a price-to-book value of 2.3, the company has shown poor long-term growth, with net sales growing at only 6.10% annually over the last five years.\n\nBroader market context indicates that while the Sensex has shown a slight decline of 0.53% over the past week, Akums Drug..."
      }
    ],
    "total": 148,
    "sid": "10039335",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/akums-drugs-pharmaceuticals-10039335"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Nine Months Ended On 31St December 2025.",
      "datetime": "31-Jan-2026",
      "details": "Akums Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the Un-audited (Standalone & Consolidated) Financial Results for the quarter and nine months ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "31-Jan-2026",
      "details": "Schedule of the Earnings / Analysts Conference Call (group meet) for Un-audited financial results of Q3 FY26.",
      "source": "BSE"
    },
    {
      "caption": "EU-GMP Certification",
      "datetime": "23-Jan-2026",
      "details": "EU-GMP Certification",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Akums Drugs Sees Revision in Market Evaluation Amidst Challenging Fundamentals

2025-11-28 10:05:12

Akums Drugs has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and market positioning. This adjustment highlights evolving perspectives on the company’s financial health, valuation, technical outlook, and overall quality within the Pharmaceuticals & Biotechnology sector.

Why is Akums Drugs falling/rising?

2025-11-25 01:51:32

Recent Price Movement and Market Performance Akums Drugs has been on a losing streak, with the stock falling for five consecutive days and registering a weekly decline of 5.91%, significantly underperforming the Sensex, which remained almost flat with a marginal 0.06% gain over the same period. The stock is trading perilously close to its 52-week low, just 1.67% above the ₹407.4 mark, underscoring the persistent bearish sentiment among investors. Intraday activity further highlighted weakness, with the share price touching a low of ₹411.1, down 2.5% during the session, and a weighted average price indicating that most volume was transacted near these lower levels. Technically, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-...

How has been the historical performance of Akums Drugs?

2025-11-17 23:27:20

Answer: The historical performance of Akums Drugs shows a significant recovery and growth in recent years, particularly in the fiscal year ending March 2025. Breakdown: In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, slightly down from 4,178.18 crore in March 2024 but up from 3,654.82 crore in March 2023. The total operating income mirrored the net sales at 4,118.16 crore for March 2025. The company's total expenditure decreased to 3,653.67 crore in March 2025 from 4,055.20 crore in March 2024, contributing to an operating profit (PBDIT) of 516.61 crore, a substantial increase from 157.01 crore in the previous year. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore compared to just 0.79 crore in the prior year. The consolidated net profit also reflected t...

Akums Drugs Faces Financial Challenges Amid Declining Performance Metrics and Rising Costs

2025-11-14 11:03:32

Akums Drugs & Pharmaceuticals has faced a decline in financial performance for the quarter ending September 2025, despite reporting a higher profit after tax for the nine-month period. Key indicators show rising interest expenses and a significant drop in quarterly PAT, raising concerns about operational efficiency and financial sustainability.

Akums Drugs Q2 FY26: Profit Plunges 37% as Margins Compress Under Rising Costs

2025-11-14 09:46:28

Akums Drugs & Pharmaceuticals Ltd., one of India's leading pharmaceutical contract development and manufacturing organisations, reported a disappointing second quarter for FY2026, with consolidated net profit declining 37.46% year-on-year to ₹40.78 crores from ₹65.21 crores in Q2 FY25. The quarter-on-quarter performance was equally concerning, with profits falling 35.76% from ₹63.48 crores in Q1 FY26. The sharp contraction in profitability comes despite relatively stable revenue, raising questions about operational efficiency and cost management at the ₹6,635 crore market capitalisation company.

How has been the historical performance of Akums Drugs?

2025-11-13 23:53:16

Answer: The historical performance of Akums Drugs shows significant fluctuations in key financial metrics over the past three years, culminating in a notable recovery in the fiscal year ending March 2025. Breakdown: In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, a slight decrease from 4,178.18 crore in March 2024, but an increase from 3,654.82 crore in March 2023. The total operating income mirrored this trend, remaining stable at 4,118.16 crore in March 2025. The total expenditure, excluding depreciation, decreased to 3,653.67 crore from 4,055.20 crore in the previous year, contributing to a significant rise in operating profit (PBDIT) to 516.61 crore, compared to 157.01 crore in March 2024 and 384.06 crore in March 2023. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surg...

Why is Akums Drugs falling/rising?

2025-11-11 00:27:55

As of 10-Nov, Akums Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 439.70, reflecting a decrease of Rs 14.75 or 3.25%. The stock has underperformed its sector by 4.3% today and has been on a consecutive downward trend for the last three days, with a total decline of 6.63% during this period. The stock has also touched an intraday low of Rs 436, indicating significant selling pressure. Over the past year, the stock has generated a return of -44.83%, which is considerably worse than the benchmark Sensex, which has gained 5.09%. Despite a low debt-to-equity ratio and an attractive valuation indicated by a price-to-book value of 2.3, the company has shown poor long-term growth, with net sales growing at only 6.10% annually over the last five years. Broader market context indicates that while the Sensex has shown a slight decline of 0.53% over the past week, Akums Drug...

View All News